Zalifrelimab

泽弗利单抗

Report date: 2026/03/28 20:00:32

Base Information

Drug NameZalifrelimab
Drug Alias NameAGEN-1884RebmAb-600UGN-301
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionAnti-CTLA4
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursUrinary Bladder NeoplasmsUrologic Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanThailand +[12] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies4-Antibody AGLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesAgenus IncUrogen Pharma LtdBetta Pharmaceuticals Co Ltd
Inactive CompaniesUT Health San Antonio
Active IndicationsSolid tumoursUrinary Bladder NeoplasmsUrologic Neoplasms +[9] 
Inactive IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungHemangiosarcoma

Other Information

ATC CodeN/A
Related LinksN/A